Table 2.
Interruption of intravenous sedating medications.
| Variable | PRE (n=98) | POST (n=100) | p-value |
|---|---|---|---|
| DI completed, n (%) | 283 (49.3) | 254 (58.4) | <0.01 |
| Opportunities for DI that were not completeda | 235 | 179 | |
| Reasons for no DI, n (%) | |||
| Hemodynamic instability | 58 (24.7) | 27 (15) | 0.02 |
| Planned surgery/procedure | 28 (11.9) | 37 (20.5) | 0.02 |
| Ventilatory dyssynchrony | 8 (3.4) | 22 (12.2) | <0.01 |
| RASS goal <–2 | 27 (11.5) | 27 (13.3) | 0.35 |
| Comfort measures/deceased | 15 (6.4) | 12 (6.7) | 0.89 |
| Sedation initiated <12 h | 53 (22.6) | 34 (18.9) | 0.45 |
| Active ischemia | 7 (3) | 1 (0.6) | 0.15 |
| Alcohol withdrawal | 3 (1.3) | 7 (3.9) | 0.11 |
| RASS currently >–1/agitation | 36 (15.3) | 11 (6.1) | <0.01 |
| Active seizures | 0 (0) | 1 (0.6) | 0.81 |
DI: drug interruption; POST: post-pathway implementation; PRE: prior to pathway implementation; RASS: Richmond Agitation Sedation Scale.
a
Restricted to analysis of instances where the reason for not completing sedating DI was recorded. The % for DI completed is among the total opportunities for DI. The reasons (%) are among opportunities for DI that were not completed and the reason was known. Reasons for deferring DI were unknown in 59 ‘opportunities’ PRE and 0 POST.